Diaceutics (LON:DXRX) Trading Up 0.7% – Time to Buy?

Diaceutics PLC (LON:DXRX)’s share price rose 0.7% during mid-day trading on Thursday . The stock traded as high as GBX 146 and last traded at GBX 146. 67,335 shares were traded during mid-day trading, a decline of 66% from the average session volume of 195,402 shares. The stock had previously closed at GBX 145.

Analysts Set New Price Targets

Separately, Canaccord Genuity Group lifted their target price on shares of Diaceutics from GBX 215 to GBX 216 and gave the stock a “buy” rating in a research note on Thursday, June 4th. Three equities research analysts have rated the stock with a Buy rating, Based on data from MarketBeat, the company currently has a consensus rating of “Buy” and an average target price of GBX 205.33.

Diaceutics Price Performance

The business has a 50-day simple moving average of GBX 157.96 and a 200 day simple moving average of GBX 152.55. The firm has a market cap of £123.56 million, a P/E ratio of 1,327.27 and a beta of 0.89. The company has a debt-to-equity ratio of 2.85, a quick ratio of 9.92 and a current ratio of 3.43.

Diaceutics (LON:DXRX) last issued its quarterly earnings data on Tuesday, May 26th. The company reported GBX 11 earnings per share for the quarter. Diaceutics had a return on equity of 0.25% and a net margin of 0.25%.The firm had revenue of GBX 3,844 million for the quarter. On average, analysts anticipate that Diaceutics PLC will post 1.0107919 earnings per share for the current fiscal year.

Diaceutics Company Profile

At Diaceutics we believe that every patient should get the opportunity to receive the right test and the right therapy to positively impact their disease outcome. We provide the world’s leading pharma and biotech companies with an end-to-end commercialisation solution for precision medicines through data analytics, scientific and advisory services enabled by our platform DXRX – The Diagnostics Network®.